MolecularMD Licenses DDR2 Markers for Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD today announced a licensing deal covering DDR2 mutations for lung cancer.

The Portland, Ore.-based company has obtained the rights to commercialize IP around the mutations for diagnostic, prognostic, and predictive uses. The IP is jointly owned by the Broad Institute and Dana-Farber Cancer Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.